Tiotropium Improves Lung Function in Patients With Severe Asthma
Treatment reduces risk of severe exacerbations (October 28)
New data on the treatment of severe asthma with tiotropium (Boerhinger Ingelheim) delivered via the Respimat inhaler have been presented at the 2013 American College of Chest Physicians (ACCP) annual meeting (CHEST 2013) in Chicago. Tiotropium is being evaluated to determine its efficacy and safety in patients with asthma and is not currently approved for this indication.
Pooled phase III data showed that, in adult asthma patients who remained symptomatic despite treatment with at least inhaled corticosteroids (ICS) or long-acting beta-2 agonists (LABAs), tiotropium delivered via the Respimat inhaler reduced the risk of severe asthma exacerbations and of any asthma exacerbation.
In addition, spirometry pulmonary-function tests were conducted to evaluate whether once-daily dosing of tiotropium resulted in sustained improvements in lung function over 24 hours. Data from these tests demonstrated that tiotropium delivered once daily via the Respimat inhaler achieved statistically significant improvements in lung function versus placebo and that these improvements were sustained for the 24-hour study period.
A pooled analysis of adverse events (AEs) from phase III studies was also presented. A lower percentage of patients in the tiotropium group (73.5%; n = 335) reported AEs compared with patients in the placebo group (80.3%; n = 336). The most common AEs were asthma (tiotropium, 39.9% vs. placebo, 50.9%); a decrease in the peak expiratory flow rate (20.4% vs. 26.8%); and nasopharyngitis (11.2% vs. 12.3%).
Source: Boehringer Ingelheim; October 28, 2013.